Immunitas Therapeutics, Inc is a biotechnology company based in Cambridge, MA, dedicated to the discovery and development of innovative therapeutics for cancer patients. With a focus on precision immunotherapy, their research combines single-cell genomics and machine learning to identify key immune cell populations involved in immuno-oncology. Their team of renowned cancer researchers and antibody pioneers utilize human tumor samples and primary cells to form and test research hypotheses, allowing them to prioritize the development of relevant biomarkers and accelerate the pace of their research. Immunitas is building a robust pipeline of immuno-oncology antibody-based therapeutics, with their lead program currently in clinical trials.
With a highly experienced management team and scientific advisory board, Immunitas is committed to fostering a culture of innovation and collaboration. They believe in the power of high-functioning teams to overcome scientific challenges and are dedicated to the growth and success of their employees. Through their strong internal expertise in antibody discovery and engineering, Immunitas is able to advance the development of therapeutic antibodies in parallel with their research efforts. Their goal is to bring novel biology to the forefront of drug development and make a meaningful impact in the field of cancer therapeutics.
Generated from the website